Transform CV Risk in Diabetes

Description

This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).

Conditions

Type 2 Diabetes

Study Overview

Study Details

Study overview

This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).

Transform CV Risk in Diabetes

Transform CV Risk in Diabetes

Condition
Type 2 Diabetes
Intervention / Treatment

-

Contacts and Locations

Washington

Multiple sites nationwide, Washington, District of Columbia, United States, 20004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * T2D diagnosis in the medical record
  • * ASCVD, defined as follows:
  • 1. Known Coronary artery disease (CAD), prior Acute coronary syndrome (ACS), or coronary artery revascularization
  • 2. Prior TIA/ischemic stroke or known carotid or intracerebral atherosclerosis, or prior carotid revascularization
  • 3. Prior Peripheral artery disease (PAD) including symptomatic claudication or pe-ripheral revascularization
  • * Current participation in an interventional clinical assessment of an investigational drug/device (excluding assessments related to COVID-19)
  • * Currently receiving any SGLT2i or GLP-1RA
  • * Known allergy/hypersensitivity/intolerance/contraindication to SGLT2i or GLP-1RA
  • * Currently receiving comfort care or enrolled in hospice
  • * Life expectancy \<1 year
  • * History of or plan for heart transplantation or ventricular assist device
  • * Current or planned hemodialysis
  • * Decompensated end stage liver disease
  • * History of Fournier's Gangrene
  • * Type 1 diabetes
  • * Prior history of diabetic ketoacidosis
  • * Pregnancy or active breastfeeding
  • * History of Pancreatitis or pancreatic cancer
  • * History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

American College of Cardiology,

Study Record Dates

2024-12-31